Taiwanese pharmaceutical company Innopharmax intends to issue five million shares of its common stock in order to raise funds for meeting its research and development expenses and working capital.

The issue will be priced between NT$23 ($0.72) and NT$32 ($1.03) a share, with 85% of the shares issued to existing shareholders and 15% to the company’s employees.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Aurinia Pharmaceuticals has announced the pricing for its proposed underwritten public offering of shares to raise funds for research and development, and working capital.

The offering includes 22.3 million shares of its common stock priced at $6.75 a share to raise $150.5m in gross proceeds.

Underwriters have a 30-day option to purchase up to an additional 3.3 million shares.

See Also:

"Aurinia Pharmaceuticals has announced the pricing for its proposed underwritten public offering of shares to raise funds for research and development, and working capital."

Aurinia Pharmaceuticals is a Canadian-based biopharmaceutical company focused on immunology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chinese pharmaceutical company Hainan Poly Pharm plans to raise ¥350.45m ($50.75m) in gross proceeds through an initial public offering (IPO) of its shares.

The IPO will include 30.5 million shares priced at ¥11.49 ($1.66) a share.

OncBioMune Pharmaceuticals has signed a non-binding agreement with Eddingpharm (Taizhou)’s subsidiary EOC Pharma for the development and commercialisation of the latter’s products in 34 countries across Mexico, Central and Latin America.

Based in the US, OncBioMune Pharmaceuticals is a biopharmaceutical company that develops novel cancer products and vaccine technology.